Rise and shine, folks, another busy day is on the way. Already, there was a burst of activity here on the Pharmalot campus, where the official mascot stared down a delivery person and then nearly cornered a furry creature running across the grounds. As for us, we are diligently brewing another cup of stimulation — we are back to blueberry cobbler — as we review our growing to-do list. No doubt, you can relate. So no time to dilly dally. Here are some items of interest to help you along on your own merry way. Have a smashing day and do keep us in mind when something interesting arises. …
An experimental Eli Lilly drug failed to prevent memory loss in a study of healthy older people with a high risk of developing clinical Alzheimer’s disease in one of the first studies aimed at stopping symptoms before they start, The Wall Street Journal writes. The drug was no better than a placebo over about 4½ years of treatment at slowing patients’ decline in areas including memory and the ability to plan and complete tasks. The drug was tested in more than 1,100 people between ages 65 and 85 with no signs of cognitive problems but who had clumps of amyloid protein in their brains. The failure was expected by some in the Alzheimer’s field after the drug failed in previous studies.
Pharmacies and medication abortion are emerging as contentious political battlegrounds in the increasingly complex issue of abortion access in the U.S., The Wall Street Journal writes. Walgreens Boots Alliance has found itself at the center of the fray after the pharmacy chain said it would not dispense the abortion pill in states where abortion is illegal and in several states where it is currently legal, including Alaska, Iowa, Kansas and Montana, given the “complexity and flux” of the laws. The move sparked backlash from several Democratic leaders and praise from some Republican politicians. On Wednesday, Calif. Gov. Gavin Newsom pulled back a planned contract renewal with Walgreens, PBS adds.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect